ARTICLE | Clinical News
Cantab begins Phase I
June 15, 2000 7:00 AM UTC
Cantab (LSE:CTB; CNTBY) started a 40-patient Phase I trial in the Netherlands of its TA-CIN genetically engineered human papillomavirus (HPV) fusion protein vaccine to treat cervical dysplasia, an abn...